Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375153 | 0.93 | CHRM2 (0.53) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL649003 | 0.88 | SLC6A4 (0.45) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL7368877 | 0.87 | SLC6A4 (0.44) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4837226 | 0.86 | SLC6A4 (0.45) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4837893 | 0.86 | CHRM2 (0.54) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL8529509 | 0.85 | CHRM2 (0.53) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL8529249 | 0.85 | SLC6A4 (0.44) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4831862 | 0.85 | SLC6A4 (0.44) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL7374494 | 0.84 | SLC6A4 (0.43) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4834581 | 0.83 | SLC6A4 (0.47) | CHRM2CHRM1SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407990-B2 | Therapeutic Agents | KNOLL GMBH (DE) | 2008-08-05 | — | — | US | claimed |
| US-20070129445-A1 | Therapeutic Agents | KNOLL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| US-6974840-B1 | Therapeutic agents | KNOLL GMBH (DE) | 2005-12-13 | — | — | US | claimed |
| US-20050182141-A1 | Therapeutic agents | LUSCOMBE GRAHAM P (GB) | 2005-08-18 | — | — | US | claimed |
| EP-1198229-A1 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-04-24 | — | — | EP | claimed |
| WO-2001001979-A1 | THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-01-11 | — | — | WO | claimed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | claimed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | claimed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | claimed |
| US-7407990-B2 | Therapeutic Agents | KNOLL GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20070129445-A1 | Therapeutic Agents | KNOLL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20050182141-A1 | Therapeutic agents | LUSCOMBE GRAHAM P (GB) | 2005-08-18 | — | — | US | disclosed |
| EP-1198229-A1 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001001979-A1 | THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5652271-A | ANTIDEPRESSANTS, NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | disclosed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129445-A1 | Therapeutic Agents | OPRM1, CNR1, SIGMAR1 | CHRM2 20/4885CHRM1 15/4885SLC6A4 189/4885 |
| US-20050182141-A1 | Therapeutic agents | OPRM1, CNR1, SIGMAR1 | CHRM2 24/4885CHRM1 18/4885SLC6A4 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.